Formosa Pharmaceuticals
台新藥股份有限公司
Formosa Pharmaceuticals is a Taiwan TWSE-listed biotechnology company; its most advanced asset is APP13007 / BYQLOVI (FDA approved, Inflammation and pain after ocular surgery), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| APP13007 / BYQLOVI | — | FDA approved | Inflammation and pain after ocular surgery | United States | 2026-05-06 | Company disclosure |
| APP13002 | — | Preclinical | Infectious eye diseases and related ocular surface disorders | — | 2026-05-06 | Company disclosure |
| TSY-110 | — | Clinical trial application submitted | HER2-positive early and metastatic breast cancer | Europe | 2026-08-28 | Company disclosure |
Key events
- TSY-110 clinical trial application submitted in Europe (company disclosure)
- APP13007 marketing authorization application submitted in Australia (company disclosure)
- APP13007 received approval-in-principle notice in Israel (company disclosure)